Replies to post #12877 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I note from other threads that you have lost interest in MNTA as a shareholder and that says a lot about the effectiveness of what TEVA has done.

Agree that Teva has succeeded in making MNTA’s Copaxone program somewhat less consequential; however, I still own 25,000 MNTA shares with a low cost basis, and I will probably continue to hold them to see what MNTA can accomplish in the FoB arena.